Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers

Carcinogenesis

Volumn 29, Issue 4, 2008, Pages 762-765

  Cybulski, Cezary ^c   Masojć, Bartłomiej ^a   Oszutowska, Dorota ^a   Jaworowska, Ewa ^a   Grodzki, Tomasz ^a   Waloszczyk, Piotr ^b   Serwatowski, Piotr ^b   Pankowski, Juliusz ^b   Huzarski, Tomasz ^a   Byrski, Tomasz ^a   Górski, Bohdan ^a   Jakubowska, Anna ^a   Dȩbniak, Tadeusz ^a   Wokołorczyk, Dominika ^a   Gronwald, Jacek ^a   Tarnowska, Czesława ^a   Serrano Fernández, Pablo ^a   Lubiński, Jan ^a   Narod, Steven A ^b  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Regional Hospital for Lung Diseases   (Poland)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; PROTEIN P53; TOBACCO SMOKE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RISK; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTOXICITY; GENOTYPE; HUMAN; LARYNX CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POLAND; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHILD; CONFIDENCE INTERVALS; DNA, NEOPLASM; FEMALE; FOUNDER EFFECT; HUMANS; LARYNGEAL NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN-SERINE-THREONINE KINASES; REFERENCE VALUES; RISK REDUCTION BEHAVIOR;

EID: 41849112710     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn044     Document Type: Article

References (24)

1. Bogdanova,N. et al. (2005) Association of two mutations in the CHEK2 gene with breast cancer. Int. J. Cancer, 116, 263-266.
2. Chaturvedi,P. et al. (1999) Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18, 4047-4054.
3. CHEK2 Breast Cancer Consortium (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100de1C in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet., 31, 55-59.
4. CHEK2 Breast Cancer Case-Control consortium (2004) CHEK2* 1100de1C and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls ftom 10 studies. Am. J. Hum. Genet., 74, 1175-1182.
5. Cybulski,C. et al. (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am. J. Hum. Genet., 75, 1131-1135.
6. Dong,X. et al. (2003) Mutations in CHEK2 associated with prostate cancer risk. Am. J. Hum. Genet., 72, 270-280.
7. Kilpivaara,O. et al. (2004) CHEK2 variant I157T may be associated with increased breast cancer risk. Int. J. Cancer, 111, 543-547.
8. Matsuoka,S. et al. (2000) Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl Acad. Sci. USA, 97, 10389-10394.
9. Oldenburg,R.A. et al. (2003) The CHEK2*1100de1C variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res., 63, 8153-8157.
10. Rudd,M.F. et al. (2006) Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukaemia. Blood, 108, 638-644.
11. Seppala,E.H. et al. (2003) CHEK2 variants associate with hereditary prostate cancer. Br. J. Cancer, 89, 1966-1970.
12. Vahteristo,P. et al. (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet., 71, 432-438.
13. Cybulski,C. et al. (2006) A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J. Med. Genet., 43, 863-866.
14. Cybulski,C. et al. (2006) A deletion in CHEK2 of 5395 basepairs predisposes to breast cancer in Poland. Breast Cancer Res. Treat, 102, 119-122.
15. Cybulski,C. et al. (2007) Germline CHEK2 mutations and colorectal cancer risk: Different effects of amissense and truncating mutations? Eur. J. Hum. Genet., 15, 237-241.
16. Kilpivaara,O. et al. (2006) CHEK2 Il57T associates with familial and sporadic colorectal cancer. J. Med. Genet., 43, e34.
17. Brennan,P. et al. (2007) Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: Case-control study. Hum. Mol. Genet., 16, 1794-1801.
18. Walsh,T. et al. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA, 295, 1379-1388.
19. Antoni,L. et al. (2007) CHK2 kinase: Cancer susceptibility and cancer therapy - two sides of the same coin? Nat. Rev. Cancer, 7, 925-936.
20. Hecht,S.S. (1999) Tobacco smoke carcinogens and lung cancer. J. Natl Cancer Inst., 91, 1194-1210.
21. Le Calvez,F. et al. (2005) TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: Distinct patterns in never, former, and current smokers. Cancer Res., 65, 5076-5083.
22. Mounawar,M. et al. (2007) Patterns of EGFR, HER2, TP53, and, KRAS mutations of p14arf expression in non-small. cell lung cancers in relation to smoking history. Cancer Res., 67, 5667-5672.
23. Feki,A. et al. (2004) Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol., 52, 103-116.
24. Zhou,B.B. et al. (2004) Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer, 4 216-225.